Vicore Pharma Holding AB (VCRE) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Vicore Pharma Holding AB (NASDAQ: VCRE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $9.59 (-2.14% 1D, market cap $2.76B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, VCRE ranks #272 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VCRE carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, VRDN (Viridian Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.79B) and MBX (MBX Biosciences Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -26.4%, cap $2.69B). Among the 5-stock peer group, VCRE leads on earnings multiple (N/A) while MBX leads on capital efficiency (-26.4% ROIC).
For Vicore Pharma Holding AB (VCRE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #272 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 1.9% FCF Margin ($77.3M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
While VCRE currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.07) and Max Pain ($10.07) forces dealer call-delta covering toward $18.69.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Vicore Pharma Holding AB (VCRE) dropped -2.14% to $9.59, trading at 17% of its 52-week range ($7.88 – $17.8). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
comAbout AB Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonar
In parallel, the iDMC conducted its regular safety and benefit-risk review of all available data and raised no concerns. ASPIRE continues as planned and remains on track to report 52-week topline results in mid-2027.
STOCKHOLM, SE / ACCESS Newswire / October 13, 2026 / AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the company will p
STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agoni
STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (AT
STOCKHOLM, SE / ACCESS Newswire / September 30, 2026 / AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the number of Vi
STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFBCb0pSUjI4bFFGdG1zcGRFNlZMUFBxUXdEcW93b09EMTZhazlIWFQxZWNoX2R0V2dQbmRPY0VFcG5HNEwxU3FzSmdncm9FcFN6MXdV?oc=5" target="_blank">Vicore Pharma Holding AB (VCR
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1PMEdXTzRLblQ1RXowbHpUekNOeWowZ0tBTHdVR1B1TDh2RHJmLUl4OWhiMHpvcVNCSkMxenE1eUdOSHJvSE1CclozVzZZQk95QXdXWEJLaWxHUEVBTEpSZGRBZDdLSjhGNTUxZC1XbVotZEFyUy1RS0hn?oc
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcUZxaExJTDhtZG1WUGpNRUhhWktJZDB5SWdqRkYwYndTQi1HTDFGQ0NEMEc5X2k2WXlyaXowTmR4ZzE3TXVDVUNnNU54dE1rNTVoSy1pUmx0cUU1VzRqZ1NYRDE3cWZTRzBIXzVYNjgzdU9XVGREYnBYQkt
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VCRE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VCRE. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Vicore Pharma Holding AB (VCRE) ranks #272 by composite RQD confidence (49/100, grade D) and #213 by equity capitalization ($2.76B). Within this direct 5-issuer industry benchmark cohort, VCRE leads on earnings valuation at N/A trailing P/E, while MBX leads on capital efficiency and profitability with -26.4% ROIC and — gross margin. VCRE currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VCRE
ACTIVE
Vicore Pharma Holding AB | D | 49/100 | — | — | — | -2.14% | $2.76B | Benchmark Subject |
| VRDN Viridian Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +2.55% | $2.79B | /vrdn-vs-vcre → |
| MBX MBX Biosciences Inc. | D- | 40/100 | — | — | -26.4% | -2.63% | $2.69B | /mbx-vs-vcre → |
| NRIX Nurix Therapeutics Inc. | D | 46/100 | — | — | -35.0% | -4.10% | $2.93B | /nrix-vs-vcre → |
| PGEN Precigen Inc. | E | 33/100 | — | — | -35.0% | -25.94% | $2.48B | /pgen-vs-vcre → |
Vicore Pharma Holding AB (VCRE) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.76B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, Vicore Pharma Holding AB (NASDAQ: VCRE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $9.59 (-2.14% 1D, market cap $2.76B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, VCRE ranks #272 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VCRE carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, VRDN (Viridian Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.79B) and MBX (MBX Biosciences Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -26.4%, cap $2.69B). Among the 5-stock peer group, VCRE leads on earnings multiple (N/A) while MBX leads on capital efficiency (-26.4% ROIC).
For Vicore Pharma Holding AB (VCRE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #272 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
VCRE last traded at $9.59 (-2.14% on volume of 7,210 shares), positioning the stock -4.77% below its 50-day simple moving average ($10.07) and -12.66% below its 200-day simple moving average ($10.98). Across its 52-week range of $7.88 to $17.80, VCRE sits at the 17.2% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.39 to $10.79).
Vicore Pharma Holding AB (VCRE) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $9.59 (-2.14% 1D, market capitalization $2.76B).
Vicore Pharma Holding AB (VCRE) is listed on NASDAQ and classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. The profile identifies it as a NASDAQ-listed issuer with a market capitalization of $2.9B.
Upstream and downstream dependencies cannot be identified from source data. Sector context is limited to the Health Care classification and the Biotechnology: Pharmaceutical Preparations industry label. No sector correlation data or second-order bottlenecks are available in source data.
Real-time company headlines, analyst actions, and sector developments for Vicore Pharma Holding AB (VCRE) • Click "Debate This Headline" to argue it in the Roar Pit below
comAbout AB Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonar
In parallel, the iDMC conducted its regular safety and benefit-risk review of all available data and raised no concerns. ASPIRE continues as planned and remains on track to report 52-week topline results in mid-2027.
STOCKHOLM, SE / ACCESS Newswire / October 13, 2026 / AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the company will p
STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agoni
STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (AT
STOCKHOLM, SE / ACCESS Newswire / September 30, 2026 / AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the number of Vi
STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFBCb0pSUjI4bFFGdG1zcGRFNlZMUFBxUXdEcW93b09EMTZhazlIWFQxZWNoX2R0V2dQbmRPY0VFcG5HNEwxU3FzSmdncm9FcFN6MXdV?oc=5" target="_blank">Vicore Pharma Holding AB (VCR
Don't sleep on VCRE's setup in Health Care. Balance-sheet forensics are the strongest pillar, with an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5, and the price of 10.2 sits well above the 52-week low of $7.88.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (49/100) backs up the fundamental quality.
Both sides have a point here — VCRE's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
I respect the product at Vicore Pharma Holding AB, but the stock at $9.80 is a different story. The cash-generation, institutional, and insider pillars are weak, with ROIC and FCF yield both at 0% and an RQD score of 51 carrying a D grade and a Sell verdict.. FCF yield is 0.0% and RQD sits at 49/100 (D) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: